bioAffinity prices ~$4.0M private placement: 8.462M shares (or pre-funded) + 2 warrants each
AI Summary
BioAffinity entered a private placement with an institutional investor to raise approximately $4.0M by selling 8,462,027 common shares (or pre-funded warrants in lieu) together with two warrants per share, priced at-the-market under Nasdaq rules. The combined effective price per share plus two warrants is $0.4727 (pre-funded combo $0.4657); pre-funded warrants have a $0.007 exercise price, the regular warrants have a $0.4727 exercise price, expire in five years, and the regular warrants will be exercisable only after stockholder approval. The offering is expected to close on or about August 14, 2026, so initial dilution is delayed until closing and additional dilution from the warrants is contingent on later shareholder approval. Timing: Dilution depends on stockholder approval first, and the press release does not say when that will happen.
Positives
- Gross proceeds expected to be approximately $4.0 million
- Offering priced at-the-market under Nasdaq rules (market-based pricing)
Negatives
- Large potential overhang: two warrants per share could cover up to 16,924,054 shares if exercised
- Regular warrants not exercisable until shareholder approval, creating future contingent dilution
- Significant share issuance (8.46M) will dilute upon expected close (on or about Aug 14, 2026)
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: stockholder approval
Dilution status
conditional
Dilution timing
Dilution status: Undetermined
Trigger type
shareholder_approval